The FDA has mandated changes in the warning labels of Yaz and other oral contraceptives after a study found that these pills can cause blood clots 1.5 times more often than conventional birth control methods. This has prompted a Yaz lawsuit and an investigation by a leading pharmaceutical company. The changes have been a boon for women who have been affected by the blood-clot risk associated with the Yaz and Yasmin combination.
The company is now settling pulmonary embolism on Yaz and related lawsuits with patients who took the anticoagulant medication. The drug has been linked to an increased risk of pulmonary embolism and venous sinus thrombosis. In the worst-case scenario, the medication could lead to a stroke or heart attack. However, Bayer has stated that the risk of pulmonary embolism is low, based on the number of lawsuits it has settled.
Until now, the company has been unwilling to acknowledge the potential risks of Yaz and Yasmin. Since the first reports of the side effects, more than 3000 cases have been settled with the company. However, more lawsuits will likely be filed as more people become injured by Yaz. Therefore, Yaz patients must contact a Yaz and Yasmin lawsuit attorney to pursue their legal rights.
Increased potassium levels in the body
There are many potential dangers associated with taking birth control pills, but one, in particular, poses a risk to women who take Yaz or Yasmin. The drug, which contains the diuretic drospirenone, can cause excessive levels of potassium in the blood. This can lead to several dangerous consequences, including stroke, heart attack, and pulmonary embolism. In addition to blood clots, hyperkalemia can cause problems with the gallbladder. If you develop this condition, you can experience a range of serious health risks, including pulmonary embolism, cardiac arrest, or even death.
The FDA has admonished Bayer Corporation for its over-promotion of Yaz and its generic version, Yasmin. This drug caused severe health complications in women, including pulmonary embolisms, deep vein thrombosis, and strokes. Some women have suffered kidney failure and damage. The drugs remain one of the most popular prescriptions in the U.S., so the company has a long way to go.
Increased risk of venous thromboembolism
If you are suffering from an increased risk of venous thromboembolic caused by the prescription drugs Yaz and/or Yasmin, you may have grounds to file a lawsuit against the manufacturers of these drugs. Several women have already filed suits against Bayer and other pharmaceutical companies. These women have cited injuries caused by the drugs that can result in a heart attack or stroke.
The FDA approved the birth control pills for women, but it found that the drug increased the risk of venous thromboembolism, including pulmonary embolism. In addition to these side effects, Yaz and Yasmin also altered hormone levels and affected the sodium and water balance of the body. The increased potassium levels in the bloodstream interfered with the heart’s rhythm, causing a dangerous level of hyperkalemia. Similarly, an elevated potassium level in the bloodstream impacted nerve and muscle function. The increased potassium levels also damaged the kidneys.
Increased risk of gallbladder disease
A lawsuit filed against Bayer for an increased risk of gallbladder disease associated with Yaz and Yasmin has been settled for $24 million. Bayer denied any link between these two medications and gallbladder problems. Nevertheless, the lawsuit has shifted the bellwether schedule for the entire MDL. Bayer must now comply with the FDA’s new requirements for TV advertisements and spend $20 million on a corrective campaign.
Women who take Yaz or Ocella for six months to two years are at an increased risk for gallbladder disease. Both drugs contain estrogen, which can increase the formation of gallstones. In addition, the active ingredient in Yaz and Ocella, drospirenone, can dehydrate the body and cause bile to concentrate, resulting in gallstone formation.
Increased risk of heart attacks
A recent study has linked two birth control pills to an increased risk of pulmonary embolism and heart attacks. Yaz and Yasmin contain the hormone drospirenone, which may increase the risk of heart attacks. While heart attacks typically do not present any warning signs or symptoms in the early stages, they often worsen over several days. Although pulmonary embolism and heart attacks can be fatal, symptoms are often mild and do not indicate a potential heart attack.
The FDA ordered the drug manufacturers to post black box warnings on Yaz and Yastrozole labels in 2012. These warnings are the most serious warnings from the FDA and must be displayed prominently. Because of this, some plaintiffs’ attorneys are no longer handling Yaz and Yasmin cases. However, many other lawsuits against drug makers have cited these warnings as evidence of increased risks of heart attacks and strokes.